bioMérieux, a world leader in the field of in vitro diagnostics, announces that VIDAS® 3, the new generation of VIDAS®, has been granted CE marking. This instrument, which further enriches the offering of the VIDAS immunoassay product range, VIDAS and mini VIDAS®, is now commercially available in Europe and the countries that recognize the CE marking.
VIDAS® 3, the New-generation VIDAS® Presented at the JIB International Biologists Congress
07 Novembre, 2012
bioMérieux, a world leader in the field of in vitro diagnostics, presented today VIDAS® 3, the new generation of its automated immunoassay system, during the Journées Internationales de Biologie (JIB) congress in Paris. This latest enhancement to the VIDAS® range offers major new features including, increased automation and greater traceability.
bioMérieux Completes its VIDAS® Hepatitis Panel with a New Test for the Diagnosis of Hepatitis C
03 Maggio, 2012
bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of VIDAS® Anti-HCV for the detection of the hepatitis C virus (HCV). With this new CE marked test, VIDAS® now has a complete hepatitis menu with tests for A, B and C viral hepatitis.
bioMérieux’s Myla® Named as Finalist in the 2012 Medical Design Excellence Awards
12 Aprile, 2012
A world leader in in vitro diagnostics, bioMérieux today announced that its microbiology middleware, Myla® has been selected as a finalist in the In Vitro Diagnostics category of the Medical Design Excellence Awards (MDEA)competition. Myla is an innovative microbiology middleware solution that offers consolidated interfacing, workflow optimization and information management. Myla is browser-based and consolidates information that can impact patient care and efficiency from ID/AST and blood culture testing in a single interface for the LIS. Users can access Myla remotely from anywhere on their network.